Prosecution Insights
Last updated: November 20, 2026

Legochem Biosciences Inc.

Technology area: Biotechnology & Pharmaceuticals

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

Legochem Biosciences Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The file involves 1 distinct examiner and 1 art unit, producing a concentrated examination profile.

CANELLA, KAREN A is the identified examiner. The prosecution response should focus on the biotechnology claims at issue, with careful attention to written support and to the technical distinctions that can be defended from the existing application.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)2 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
PECKHAM, RICHARD GRANT 1 67.8% +35.9%
CANELLA, KAREN A 1 62.3% +32.8%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
17758241 PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF PECKHAM, RICHARD GRANT 15d overdue
17607678 LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE CANELLA, KAREN A —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
17758241 PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF PECKHAM, RICHARD GRANT 15d overdue
17607678 LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE CANELLA, KAREN A —

Top Art Units

Art UnitApps
1627 1
1643 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17758241 PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF PECKHAM, RICHARD GRANT 1627 §103§112 Non-Final OA 15d overdue Pending Dec 28, 2022
17607678 LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE CANELLA, KAREN A 1643 §102§112 Final Rejection — Pending Oct 29, 2021

Managing Legochem Biosciences Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Legochem Biosciences Inc. have?

Legochem Biosciences Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Legochem Biosciences Inc. applications?

Richard Grant Peckham has the most, with 1 of Legochem Biosciences Inc.'s pending office actions.

What technology area are Legochem Biosciences Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month